What is Gero?
Headquartered in Singapore with a strategic presence in San Francisco, Gero operates at the vanguard of AI-driven drug discovery. The company distinguishes itself through a physics-first methodology, integrating clinical, molecular, and genetic datasets to construct comprehensive AI models of human health. Central to its technological stack is ProtoBind-Diff, a generative AI engine designed to facilitate small-molecule discovery directly from protein sequences. By focusing on the fundamental biology of aging, Gero aims to address the root causes of chronic, age-related diseases rather than merely treating symptoms. Its scientific rigor is evidenced by high-impact publications in journals such as Science and Nature Communications, establishing a strong intellectual property moat in the competitive biotech landscape.
How much funding has Gero raised?
Gero has raised a total of $25.2M across 2 funding rounds:
Series A
$8.2M
Other Financing Round
$17M
Series A (2023): $8.2M with participation from Melnichek Investments and Bulba Ventures
Other Financing Round (2026): $17M led by Melnichek Investments
Key Investors in Gero
Melnichek Investments
A venture firm focused on supporting machine learning and biotech startups, leveraging capital from successful exits to empower founders in the healthcare and therapeutic sectors.
Bulba Ventures
An investment group specializing in early-stage technology and life sciences, providing strategic guidance to companies building transformative AI-driven platforms.
What's next for Gero?
With the successful closure of this latest financing, Gero is well-positioned to scale its AI-enabled target discovery platform and advance its internal pipeline of therapeutic candidates. The strategic focus will likely shift toward deepening pharmaceutical partnerships and refining the generative capabilities of its ProtoBind-Diff model. As the company transitions into this mature stage of development, the emphasis will remain on translating complex biological insights into actionable clinical interventions. Investors are closely watching how Gero will utilize this capital to bridge the gap between computational modeling and tangible patient outcomes in the treatment of age-related pathologies.
See full Gero company page
